Vascular  ||| S:0 E:9 ||| JJ
calcifications  ||| S:9 E:24 ||| NN
in  ||| S:24 E:27 ||| IN
chronic  ||| S:27 E:35 ||| JJ
kidney  ||| S:35 E:42 ||| NN
disease  ||| S:42 E:50 ||| NN
Vascular  ||| S:50 E:59 ||| NNP
calcifications  ||| S:59 E:74 ||| NNS
are  ||| S:74 E:78 ||| VBP
associated  ||| S:78 E:89 ||| VBN
with  ||| S:89 E:94 ||| IN
increased  ||| S:94 E:104 ||| JJ
cardiovascular  ||| S:104 E:119 ||| JJ
morbidity  ||| S:119 E:129 ||| NN
and  ||| S:129 E:133 ||| CC
mortality ||| S:133 E:142 ||| NN
.  ||| S:142 E:144 ||| .
Their  ||| S:144 E:150 ||| PRP$
prevalence  ||| S:150 E:161 ||| NN
is  ||| S:161 E:164 ||| VBZ
higher  ||| S:164 E:171 ||| JJR
in  ||| S:171 E:174 ||| IN
patients  ||| S:174 E:183 ||| NNS
with  ||| S:183 E:188 ||| IN
chronic  ||| S:188 E:196 ||| JJ
kidney  ||| S:196 E:203 ||| NN
disease  ||| S:203 E:211 ||| NN
than  ||| S:211 E:216 ||| IN
in  ||| S:216 E:219 ||| IN
the  ||| S:219 E:223 ||| DT
general  ||| S:223 E:231 ||| JJ
population  ||| S:231 E:242 ||| NN
and  ||| S:242 E:246 ||| CC
they  ||| S:246 E:251 ||| PRP
are  ||| S:251 E:255 ||| VBP
linked  ||| S:255 E:262 ||| VBN
not  ||| S:262 E:266 ||| RB
only  ||| S:266 E:271 ||| RB
to  ||| S:271 E:274 ||| TO
classical  ||| S:274 E:284 ||| JJ
risk  ||| S:284 E:289 ||| NN
factors  ||| S:289 E:297 ||| NNS
such  ||| S:297 E:302 ||| JJ
as  ||| S:302 E:305 ||| IN
hypertension ||| S:305 E:317 ||| NN
,  ||| S:317 E:319 ||| ,
diabetes ||| S:319 E:327 ||| NN
,  ||| S:327 E:329 ||| ,
dyslipidemia  ||| S:329 E:342 ||| NN
and  ||| S:342 E:346 ||| CC
smoking  ||| S:346 E:354 ||| NN
but  ||| S:354 E:358 ||| CC
also  ||| S:358 E:363 ||| RB
to  ||| S:363 E:366 ||| TO
derangements  ||| S:366 E:379 ||| VB
in  ||| S:379 E:382 ||| IN
mineral  ||| S:382 E:390 ||| NN
metabolism  ||| S:390 E:401 ||| NN
and  ||| S:401 E:405 ||| CC
to  ||| S:405 E:408 ||| TO
chronic  ||| S:408 E:416 ||| JJ
inflammation ||| S:416 E:428 ||| NN
.  ||| S:428 E:430 ||| .
The  ||| S:430 E:434 ||| DT
development  ||| S:434 E:446 ||| NN
of  ||| S:446 E:449 ||| IN
vascular  ||| S:449 E:458 ||| JJ
calcifications  ||| S:458 E:473 ||| NN
is  ||| S:473 E:476 ||| VBZ
an  ||| S:476 E:479 ||| DT
active  ||| S:479 E:486 ||| JJ
phenomenon  ||| S:486 E:497 ||| NN
that  ||| S:497 E:502 ||| WDT
is  ||| S:502 E:505 ||| VBZ
linked  ||| S:505 E:512 ||| VBN
to  ||| S:512 E:515 ||| TO
an  ||| S:515 E:518 ||| DT
imbalance  ||| S:518 E:528 ||| NN
between  ||| S:528 E:536 ||| IN
promoting  ||| S:536 E:546 ||| VBG
and  ||| S:546 E:550 ||| CC
inhibitory  ||| S:550 E:561 ||| JJ
factors ||| S:561 E:568 ||| NNS
.  ||| S:568 E:570 ||| .
They  ||| S:570 E:575 ||| PRP
affect  ||| S:575 E:582 ||| VBP
also  ||| S:582 E:587 ||| RB
young  ||| S:587 E:593 ||| JJ
patients  ||| S:593 E:602 ||| NNS
on  ||| S:602 E:605 ||| IN
dialysis  ||| S:605 E:614 ||| NN
and  ||| S:614 E:618 ||| CC
it  ||| S:618 E:621 ||| PRP
is  ||| S:621 E:624 ||| VBZ
therefore  ||| S:624 E:634 ||| RB
necessary  ||| S:634 E:644 ||| JJ
to  ||| S:644 E:647 ||| TO
recognize  ||| S:647 E:657 ||| VB
them  ||| S:657 E:662 ||| PRP
at  ||| S:662 E:665 ||| IN
an  ||| S:665 E:668 ||| DT
early  ||| S:668 E:674 ||| JJ
stage ||| S:674 E:679 ||| NN
.  ||| S:679 E:681 ||| .
The  ||| S:681 E:685 ||| DT
distinction  ||| S:685 E:697 ||| NN
between  ||| S:697 E:705 ||| IN
intima  ||| S:705 E:712 ||| NN
and  ||| S:712 E:716 ||| CC
media  ||| S:716 E:722 ||| NNS
calcification  ||| S:722 E:736 ||| NN
can  ||| S:736 E:740 ||| MD
be  ||| S:740 E:743 ||| VB
important  ||| S:743 E:753 ||| JJ
for  ||| S:753 E:757 ||| IN
a  ||| S:757 E:759 ||| DT
different  ||| S:759 E:769 ||| JJ
therapeutic  ||| S:769 E:781 ||| JJ
approach ||| S:781 E:789 ||| NN
.  ||| S:789 E:791 ||| .
There  ||| S:791 E:797 ||| EX
are  ||| S:797 E:801 ||| VBP
a  ||| S:801 E:803 ||| DT
number  ||| S:803 E:810 ||| NN
of  ||| S:810 E:813 ||| IN
devices  ||| S:813 E:821 ||| NNS
for  ||| S:821 E:825 ||| IN
the  ||| S:825 E:829 ||| DT
identification  ||| S:829 E:844 ||| NN
of  ||| S:844 E:847 ||| IN
vascular  ||| S:847 E:856 ||| JJ
calcifications ||| S:856 E:870 ||| NN
,  ||| S:870 E:872 ||| ,
including  ||| S:872 E:882 ||| VBG
x-ray  ||| S:882 E:888 ||| JJ
imaging ||| S:888 E:895 ||| NN
,  ||| S:895 E:897 ||| ,
ultrasonography  ||| S:897 E:913 ||| NN
and  ||| S:913 E:917 ||| CC
computerized  ||| S:917 E:930 ||| JJ
technologies ||| S:930 E:942 ||| NNS
.  ||| S:942 E:944 ||| .
The  ||| S:944 E:948 ||| DT
purpose  ||| S:948 E:956 ||| NN
of  ||| S:956 E:959 ||| IN
this  ||| S:959 E:964 ||| DT
paper  ||| S:964 E:970 ||| NN
is  ||| S:970 E:973 ||| VBZ
to  ||| S:973 E:976 ||| TO
show  ||| S:976 E:981 ||| VB
the  ||| S:981 E:985 ||| DT
advantages  ||| S:985 E:996 ||| NNS
and  ||| S:996 E:1000 ||| CC
disadvantages  ||| S:1000 E:1014 ||| NNS
of  ||| S:1014 E:1017 ||| IN
ultrasonography  ||| S:1017 E:1033 ||| NN
in  ||| S:1033 E:1036 ||| IN
comparison  ||| S:1036 E:1047 ||| NN
to  ||| S:1047 E:1050 ||| TO
other  ||| S:1050 E:1056 ||| JJ
tools  ||| S:1056 E:1062 ||| NNS
for  ||| S:1062 E:1066 ||| IN
the  ||| S:1066 E:1070 ||| DT
diagnosis  ||| S:1070 E:1080 ||| NN
of  ||| S:1080 E:1083 ||| IN
vascular  ||| S:1083 E:1092 ||| JJ
calcifications ||| S:1092 E:1106 ||| NN
.  ||| S:1106 E:1108 ||| .
